With 2.62 million shares changed hands, the volume of the stock remained heavier than its average volume of 2.31 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $6.79 whereas the lowest price it dropped to was $5.7408. The 52-week range on EVOK shows that it touched its highest point at $12.32 and its lowest point at $1.94 during that stretch. It currently has a 1-year price target of $18.00. Beta for the stock currently stands at -0.10.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of EVOK was up-trending over the past week, with a rise of 127.14%, but this was up by 102.63% over a month. Three-month performance surged to 195.17% while six-month performance rose 32.83%. The stock gained 38.24% in the past year, while it has lost -5.71% so far this year. A look at the trailing 12-month EPS for EVOK yields -3.18 with Next year EPS estimates of 1.49. For the next quarter, that number is -0.30. This implies an EPS growth rate of 64.06% for this year and 247.52% for next year.
Float and Shares Shorts:
At present, 1.49 million EVOK shares are outstanding with a float of 1.41 million shares on hand for trading. On 2025-06-13, short shares totaled 17702.0, which was 119.00000000000001 higher than short shares on 1747267200. In addition to Mr. Matthew J. D’Onofrio MBA as the firm’s Co-Founder, CEO & Director, Mr. Mark A. Kowieski CPA serves as its CFO, Treasurer & Secretary.
Institutional Ownership:
Through their ownership of 0.16229999 of EVOK’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, EVOK reported revenue of $3080158.0 and operating income of -$1301743.0. The EBITDA in the recently reported quarter was -$1182890.0 and diluted EPS was -$0.51.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With EVOK analysts setting a high price target of 18.0 and a low target of 18.0, the average target price over the next 12 months is 18.0. Based on these targets, EVOK could surge 194.6% to reach the target high and rise by 194.6% to reach the target low. Reaching the average price target will result in a growth of 194.6% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$3.98 being high and -$3.98 being low. For EVOK, this leads to a yearly average estimate of -$3.98.
